Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of accelerated versus standard dose escalation for house dust mite allergen immunotherapy
2020-004328-41Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Apr 2021
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Novo-Helisen Depot house dust mites in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by Allergopharma. Primary endpoint: Descriptive safety variables. Started Apr 2021; status: completed.
02
Drugs
Novo-Helisen Depot house dust mites
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2020-004328-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004328-41.